Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review

To improve the patient-centeredness of care, patient-reported outcomes have been increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2020-11, Vol.76 (20), p.2379-2390
Main Authors: Spertus, John A, Jones, Philip G, Sandhu, Alexander T, Arnold, Suzanne V
Format: Article
Language:English
Subjects:
Cardiomyopathies - psychology
Cardiomyopathies - therapy
Clinical Trials as Topic
Humans
Patient Reported Outcome Measures
Surveys and Questionnaires
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To improve the patient-centeredness of care, patient-reported outcomes have been increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure, the Kansas City Cardiomyopathy Questionnaire (KCCQ) has been qualified by the U.S. Food and Drug Administration as a Clinical Outcome Assessment and recommended as a performance measure for quantifying the quality of care. By systematically asking the same questions reproducibly over time, the KCCQ can validly and sensitively capture the impact of heart failure on patients' lives and is strongly associated with clinical events over time. This review describes how to interpret the KCCQ, how it should be analyzed in clinical trials to maximize the interpretability of results, and how it can be used in clinical practice and population health. By providing a deeper understanding of the KCCQ, it is hoped that its use can further improve the patient-centeredness of heart failure care.
ISSN:1558-3597
DOI:10.1016/j.jacc.2020.09.542